Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Outlines
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Indonesia is One of The Largest Diabetes Population
China 96,2
India 66,8
USA 25,7
Brazil 11,6
Indonesia 9,1 5
Mexico 9
7 Egypt 7,5
German 7,2
7
Turkey 7,2
Japan 7,2
Sources :
1. IDF Diabetes Atlas, 6th ed
2. IDF Diabetes Atlas 6th ed UPDATE
3. IDF Diabetes Atlas, 7th ed
Top ten countries/territories for the number of the people with
impaired glucose tolerance (PRE-DIABETES) (20-79 y.o), 2015 and
2024
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Pharmacological interventions in T2D
Plasma glucose
α-Glucosidase Glitazones
Carbohydrate Glucose Glucose
inhibitors
absorption production uptake (+)
(–)
(–)
Metformin Insulin (+)
secretion
Insulin
(+)
Sulphonylureas
Meglitinides
GLP-1 analogues
DPP-4 inhibitors
Insulin remains the most efficacious glucose
lowering agent
Decrease in HbA1c: Potency of monotherapy
HbA1c %
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Type 2 Diabetes is a Progressive Disease
Lebovitz. Diabetes Reviews 1999;7:139–53 (data are from the UKPDS population: UKPDS 16.
Diabetes 1995;44:1249–58)
SOLVE: HbA1c at time of insulin initiation
Baseline HbA1c at time of
insulin initiation
10.0 9,8 9,8 • The average HbA1c was 8.9%
9.5 9,4 • Prior to insulin initiation, patients
9,2 9,1 had received OAD therapy for
8,9 8,9 8.7±6.7 years
HbA1c (%)
9.0
8,5 8,4 • Patients remain poorly controlled
8.5 8,3 on OAD treatment for prolonged
periods of time
8.0
7.5
10.0 +0.2%
−0.5%*
−1.0%*
9.0 Pre-treatment
Mean HbA1c (%)
Post-treatment
8.0
7.0
6.0
Two OADs Three OADs Four OADs Insulin
*p<0.001
Calvert et al. Br J Gen Pract 2007;57:455–60
Outlines
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Outlines
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Levemir®
LysB29(N-tetradecanoyl)des(B30) human insulin
Minor protraction
Circulation
Albumin binding
Insulin detemir
0.4 U/kg 0.8 U/kg 1.4 U/kg
Insulin glargine
3.0
No
Glucose infusion
(mg/kg/min)
2.5 significant
2.0 between-
rate
1.5 treatment
difference at
1.0
each dose
0.5 level
0
0 2 4 6 8 10 12 14 16 18 20 22 24
Time from insulin injection (hours)
12
Time of day
24-h glucose profiles. Each point represents the treatment groups’ mean glucose for each hour and standard error of 29 subjects treated with
once-daily insulin detemir or glargine starting at 20:00 hours. The basal period is from 24:00 hours to 06:00 hours.
20
Adapted from Heise T et al. Diabetes. 2004;53:1614-20.
Outlines
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using
insulin detemir
• Insulin detemir in special population
• Summary
Type 2 diabetes: basal–oral – HbA1c
Similar or less change in HbA1c with IDet compared with IGlar and NPH insulin
NS NS NS p<0.05
9.5
OD BID
9.0 Insulin detemir
NPH insulin
8.5
HbA1c (%)
Insulin glargine
8.0
7.5
7.0
6.5
10.0
9.5 Insulin glargine
9.0
8.5
8.0
7.5
7.0
6.5
6.0
1.3 NS
1.2 Insulin detemir
p<0.02 p=0.031 p<0.001 p<0.001 NS NS p<0.05
1.1
1.0
NPH insulin
0.9
Insulin glargine
Relative risk
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Overall Nocturnal Overall Nocturnal Overall Nocturnal Overall Nocturnal
Philis-Tsimikas 2006 Hermansen 2006 Rosenstock 2008 Meneghini 2013
p<0.05
Insulin detemir
p<0.005 p<0.001 NS p<0.001
4.0
NPH insulin
3.5
Weight change (kg)
No significant No significant Insulin detemir Insulin detemir significantly Insulin detemir significantly
Philis-Tsimikas 2006 NPH difference difference significantly better better than comparator better than comparator
than comparator
No significant No significant Insulin detemir Insulin detemir significantly Insulin detemir significantly
Hermansen 2006 NPH difference difference significantly better better than comparator better than comparator
than comparator
No significant No significant Insulin detemir No significant difference No significant difference
difference difference significantly better
Rosenstock 2008 IGlar than comparator
FPG, fasting plasma glucose; IGlar, insulin glargine; NPH, neutral protamine Hagedorn
A1chieve study overview and design
0.0 -80
Change from baseline to
-1.0
week 24
-100
-101*
-2.0
-2.2*
-115*
-3.0 -120
*p<0.001
Soewondo P, et al. Clinical experience with insulin detemir: Results from the Indonesian cohort of the international A1chieve study.
Diabetes Research and Clinical Practice 2013; 100(S1): S47–S53
Starting Insulin Detemir from insulin naive patients
A1chieve Indonesia: hypoglycaemia results
6.0
Percent with at least one event
5.10
5.0 4.80
4.0
3.0
2.0
1.0
0.30
0.00 0.00 0.00
0.0
Baseline Week 24 Baseline Week 24 Baseline Week 24
Soewondo P, et al. Clinical experience with insulin detemir: Results from the Indonesian cohort of the international A1chieve study.
Diabetes Research and Clinical Practice 2013; 100(S1): S47–S53
A1chieve: Self-rated health in Insulin naïve participants
initiated on IDet
Patients on
Best imaginable Levemir®
health 100
90
80
24 weeks
70 Baseline
60
50
40
30 Baseline 24 weeks
20
Worst imaginable
health 10
0
Soewondo P, et al. Clinical experience with insulin detemir: Results from the Indonesian cohort of the international A1chieve study.
Diabetes Research and Clinical Practice 2013; 100(S1): S47–S53
Summary of A1chieve study in Indonesia
Insulin naïve participants initiated on IDet (Indonesia)
Significant improvement
(p<0.001)
*p<0.001
Soewondo P, et al. Clinical experience with insulin detemir: Results from the Indonesian cohort of the international A1chieve study.
Diabetes Research and Clinical Practice 2013; 100(S1): S47–S53
How to Titrate Basal Insulin
Levemir® Dose Titration Guidelines:
3-0-3 Algorithm
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Levemir® is approved in special population
• Prevalence
• Current management
• Rationale for early initiation
• Insulin guideline
• Insulin detemir profile
• Glycaemic control, weight benefit, hypoglycaemia using insulin
detemir
• Insulin detemir in special population
• Summary
Summary
Insulin therapy is the most efficacious therapy and can reduce HbA1c up to
2,5%
Starting with basal insulin detemir 10 U once daily and titrate based on
patient condition to reach glycemic control